The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: trastuzumab     Quarter: 2016Q3

Total Drug/Injury Combinations: 450     Number of Pages: 23

DRUGNAME PT EventCount
TRASTUZUMAB Influenza like illness 1 view events
Trastuzumab Injection site discolouration 1 view events
Trastuzumab Injection site haematoma 1 view events
Trastuzumab Injection site pruritus 1 view events
Trastuzumab Injection site swelling 1 view events
Trastuzumab International normalised ratio increased 1 view events
Trastuzumab Intestinal ischaemia 1 view events
TRASTUZUMAB Jaundice 1 view events
Trastuzumab Joint injury 1 view events
Trastuzumab Joint instability 1 view events
TRASTUZUMAB Joint stiffness 1 view events
Trastuzumab Left ventricular dysfunction 1 view events
Trastuzumab Limb injury 1 view events
TRASTUZUMAB Liver function test abnormal 1 view events
Trastuzumab Liver function test increased 1 view events
Trastuzumab Lymphangitis 1 view events
TRASTUZUMAB Malaise 1 view events
Trastuzumab Mental impairment 1 view events
TRASTUZUMAB Metastases to bone 1 view events
Trastuzumab Metastasis 1 view events

Total Drug/Injury Combinations: 450     Number of Pages: 23

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)